Major Insurers Are Expanding GLP-1 Coverage: Here's What's Changing

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your treatment plan.

The Changing Insurance Coverage Landscape

For most of their existence, GLP-1 medications for weight management occupied an uncomfortable middle ground in the U.S. insurance system. When prescribed for type 2 diabetes — Ozempic, Trulicity, Victoza — they were generally well covered, because diabetes is an accepted medical condition with well-established treatment protocols. But when prescribed for obesity alone — Wegovy, Saxenda, and more recently Zepbound — coverage was far patchier, reflecting a longstanding and scientifically indefensible view that obesity is a lifestyle choice rather than a chronic disease requiring medical treatment.

That view is changing, and changing rapidly. A combination of forces — powerful new clinical trial data demonstrating cardiovascular benefits, growing recognition of obesity as a biologically driven disease, employer awareness of the return on investment from treating obesity, and significant political pressure from patient advocacy groups — has begun to crack open the coverage landscape. What was a trickle of coverage expansion in 2022 and 2023 has become a meaningful trend by 2024, with dozens of major employers and several state Medicaid programs announcing expansions of GLP-1 coverage for obesity indications.

The significance of this shift cannot be overstated for patients who previously had no realistic path to affording these medications. With brand-name Wegovy or Zepbound costing approximately $900 to $1,300 per month at list price, insurance coverage is not a nice-to-have — it is the difference between access and no access for the vast majority of patients. A plan that adds GLP-1 obesity coverage is effectively opening the door to treatment for potentially thousands of its enrolled members.

It is important to note that "coverage expansion" does not mean unconstrained access. Even plans that have added GLP-1 coverage for obesity typically do so with prior authorization requirements, step therapy mandates (requiring trial of lifestyle intervention first), BMI thresholds, and in some cases quantity limits or treatment duration caps. Understanding the specific terms of your plan's coverage — not just whether it covers GLP-1 medications in principle — is essential for navigating the system effectively.

Employer Health Plans Adding Coverage

The employer health plan market — which covers approximately 160 million Americans through workplace benefits — has been one of the most important arenas for GLP-1 coverage expansion. Large self-insured employers, who bear the direct cost of their employees' healthcare claims and have both the incentive and the flexibility to make rapid coverage decisions, have led this trend.

In 2023, a Kaiser Family Foundation survey found that approximately 18 percent of large employers (200 or more workers) covered GLP-1 medications for weight management in their health plans. By 2024, that proportion had grown substantially, with multiple surveys suggesting coverage in 25 to 30 percent of large employers — a meaningful increase, though still leaving the majority of employer plans without coverage. The trend is clearly upward, and benefits consultants are reporting significant interest from employers in evaluating coverage additions for their 2025 and 2026 plan years.

The most aggressive movers on employer GLP-1 coverage have tended to be large technology companies and financial services firms — industries competing intensely for talent and willing to offer premium benefits to attract and retain employees. Walmart, one of the largest private employers in the United States, added Wegovy coverage for eligible employees in 2023, a decision that attracted significant attention given Walmart's historically cost-conscious benefits approach. JPMorgan Chase, Google, and several other high-profile employers have also added or expanded GLP-1 obesity coverage.

The challenge for many employers considering GLP-1 coverage is the projected cost. At current list prices, covering GLP-1 medications for all eligible obese employees in a large workforce would add millions of dollars to annual benefits costs. Employers adding coverage are typically doing so with guardrails — BMI thresholds, prior authorization requirements, step therapy requirements, and sometimes lifestyle program participation mandates — designed to limit coverage to patients most likely to benefit and to ensure that the drugs are used as part of a comprehensive approach rather than as a standalone solution.

For employees, the key action item is to review your Summary of Benefits and Coverage (SBC) document — which your employer is required to provide annually — for information on prescription drug coverage. If the SBC does not address GLP-1 medications specifically, contact your HR benefits team or call the member services number on your insurance card and ask directly whether your plan covers GLP-1 medications for obesity (not just for diabetes) and what the specific prior authorization requirements are.

State Medicaid Programs Expanding Access

Medicaid, which covers approximately 90 million low-income Americans across 50 state programs, is a critical access pathway for GLP-1 medications given that obesity disproportionately affects lower-income populations. Federal law requires state Medicaid programs to cover drugs approved by the FDA for their labeled indications if the manufacturer has signed a Medicaid Drug Rebate Agreement — which Novo Nordisk and Eli Lilly have done. However, states retain significant flexibility in how they implement coverage, including through prior authorization policies, preferred drug lists, and quantity limits.

As of 2024, coverage of GLP-1 medications for obesity (as opposed to diabetes) through state Medicaid programs remains highly variable. States including California, Colorado, Michigan, New York, and Oregon have moved toward broader coverage of GLP-1 medications for obesity, while many other states continue to restrict coverage to diabetes indications only. This creates a significant geographic inequity in access — a patient in California on Medicaid may have a clear path to Wegovy, while an equivalent patient in Texas or Florida does not.

The federal government has also been a significant actor in this space. The Biden administration proposed rules in late 2024 that would require Medicare and Medicaid to cover anti-obesity medications, including GLP-1 drugs, for weight management — a major policy shift given that Medicare Part D has historically been prohibited by statute from covering weight loss drugs. The implementation of these rules is subject to ongoing policy and legal processes, but if finalized, they would represent a fundamental transformation in GLP-1 access for the Medicare and Medicaid populations.

For patients on Medicaid, the most important steps are to work with a prescriber who is familiar with your state's Medicaid formulary for GLP-1 medications and who can help structure the prior authorization request in a way that aligns with your state's specific criteria. State Medicaid programs typically publish their preferred drug lists and prior authorization criteria online, and prescribers who regularly treat obesity are generally familiar with the landscape in their state.

What's Driving This Coverage Expansion?

The coverage expansion is not happening in a vacuum — it is being driven by a convergence of scientific, economic, and political factors that have fundamentally changed the calculus for payers and employers who were previously reluctant to cover these medications.

The most important single scientific development was the SELECT trial, published in the New England Journal of Medicine in August 2023. SELECT was a landmark cardiovascular outcomes trial that enrolled over 17,000 adults with established cardiovascular disease and obesity (but without diabetes) and randomized them to semaglutide 2.4 mg weekly or placebo. After an average follow-up of approximately 40 months, semaglutide reduced the composite risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20 percent. This was the first time any weight loss medication had demonstrated a significant reduction in hard cardiovascular endpoints in a dedicated cardiovascular outcomes trial.

The SELECT trial changed the framing of GLP-1 medications for obesity from "cosmetic" to "potentially life-saving cardiovascular therapy" — and this reframing has had a profound effect on how payers think about coverage. An insurer or employer that refuses to cover a medication that reduces heart attack and stroke risk by 20 percent faces a very different conversation with its members than one refusing to cover a medication that produces weight loss. The cardiovascular risk reduction data provided the evidence-based argument that had been missing from the case for broader GLP-1 coverage.

The economic argument has also matured significantly. Actuarial analyses and employer-sponsored research have increasingly shown that the cost of GLP-1 medications — while high — is offset over a three to five year horizon by reductions in cardiovascular events, hospitalizations, diabetes complications, musculoskeletal interventions (joint replacements), and related healthcare utilization. For self-insured employers who bear the direct cost of their employees' healthcare, this return-on-investment argument is increasingly persuasive, particularly for high-risk employee populations.

Political and advocacy pressure has also played a role. Patient advocacy organizations including the Obesity Action Coalition and the Obesity Medicine Association have been active in lobbying employers, insurers, and legislators to expand access. The growing number of patients — and their families — who are personally affected by access barriers creates constituent pressure that influences both corporate and legislative decision makers. As GLP-1 medications become more widely discussed in popular culture and media, the visibility of access inequities increases.

How to Check and Maximize Your Coverage

The first step in determining whether your GLP-1 costs might be covered is to check your plan's drug formulary — the official list of covered medications and their tier placement. Most insurance plans make their formulary available online through the member portal, and you can search for specific drug names (Wegovy, Ozempic, Zepbound, Mounjaro) to see whether they appear on the formulary and at what cost-sharing tier. Note that a drug appearing on the formulary does not mean it is covered without prior authorization — many GLP-1 medications require prior authorization even if they are on the formulary.

Calling your insurance plan's member services is often more definitive than checking the online formulary, which may not be fully up to date. Ask specifically: "Does my plan cover [drug name] for obesity — not diabetes — and if so, what are the prior authorization requirements?" Request that the representative note the call and the information provided in your account, as this creates a record that can be useful if a claim is later disputed. Ask for the prior authorization criteria in writing if possible, so you know exactly what documentation your prescriber needs to submit.

If your plan does cover GLP-1 medications with prior authorization, work with your prescriber to submit the strongest possible authorization request. This typically requires documentation of your BMI (or weight and height), relevant comorbidities (cardiovascular disease, pre-diabetes, hypertension, dyslipidemia, sleep apnea), history of prior weight loss attempts, and why GLP-1 therapy is clinically appropriate in your specific situation. The SELECT trial's cardiovascular benefit data can be a powerful addition to the clinical rationale if you have cardiovascular disease or multiple cardiovascular risk factors.

For employees who believe their employer should be covering GLP-1 medications but currently does not, having a conversation with your HR benefits manager or benefits committee is a legitimate and potentially effective course of action. Bring data — information about the SELECT trial, the ROI analyses showing cost offsets from cardiovascular event reduction, and statistics about the prevalence of obesity in the workforce and its associated productivity and healthcare cost impacts. Individual advocacy matters: benefits teams are often more open to coverage additions than employees realize, particularly when employees make the case clearly and professionally.

If your prior authorization is denied, do not accept the first denial as final. The appeals process is a meaningful tool, and a significant proportion of denials are overturned when a robust appeal is filed. Request a peer-to-peer review — in which your prescriber speaks directly with the insurance plan's medical director — as this often produces better outcomes than written appeals alone. If internal appeals are exhausted without resolution, external review through your state's insurance commissioner is available in most states and provides an additional layer of recourse.

If Your Insurance Still Doesn't Cover GLP-1

Despite the trend toward expansion, millions of patients remain without adequate insurance coverage for GLP-1 medications for obesity as of late 2024. If you are in this situation, you are not out of options — but navigating the alternatives requires persistence and a willingness to explore multiple pathways simultaneously.

Manufacturer savings programs are the most immediately impactful resource for commercially insured patients. Novo Nordisk's Wegovy Savings Card can reduce out-of-pocket costs to as low as $0 per month for the first month and $25 per month thereafter for eligible patients with commercial insurance. Eli Lilly's Zepbound Savings Card operates similarly. These programs have eligibility restrictions — they are not available to patients covered by government insurance programs (Medicare, Medicaid, TRICARE) — and the plans' copay accumulator programs can complicate their use, but for eligible commercially insured patients, they are the fastest path to dramatically reduced cost.

Patient assistance programs from both manufacturers provide the medications at no cost to uninsured or underinsured patients who meet income criteria. Novo Nordisk's NovoCare program and Eli Lilly's LillyAnswers program both operate on a similar model: the prescribing provider submits an application documenting the patient's income, insurance status, and clinical need, and the manufacturer ships the medication directly to the prescriber or patient if approved. These programs can take four to six weeks to process, so they are not a same-day solution, but they are a genuine resource for patients who otherwise have no path to affordability.

For patients with type 2 diabetes who need GLP-1 therapy for glycemic management, the coverage pathway may be cleaner through the diabetes indication. If you have documented type 2 diabetes, your prescriber can prescribe Ozempic or Mounjaro under the diabetes indication, which is covered by most plans. The weight loss benefit is a side effect in this context rather than the primary indication, but the clinical benefit to the patient is real regardless of how the prescription is classified. Work with your prescriber to determine the most appropriate and accessible prescribing pathway given your specific diagnosis and plan coverage.

Finally, stay informed and be prepared to revisit the coverage question annually. Benefits plans change on January 1 of each year, and a plan that does not cover GLP-1 medications for obesity today may add coverage for the following plan year. Open enrollment — typically in the fall for most employer plans — is the time to review your options. If you have the ability to choose between multiple plan options, comparing their formularies for GLP-1 coverage is worth doing explicitly rather than defaulting to your prior year's plan. A plan with higher premiums that covers GLP-1 medications may be significantly more cost-effective overall than a lower-premium plan that does not.